VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naive HIV-Infected Patients
Por:
Jiménez-Sousa MA, Jiménez JL, Fernández-Rodríguez A, Brochado-Kith O, Bellón JM, Gutierrez F, Díez C, Bernal-Morell E, Viciana P, Muñoz-Fernández MA and Resino S
Publicada:
5 mar 2019
Resumen:
Background: Vitamin D is a fundamental regulator of host defenses by activating genes related to innate and adaptive immunity. In this study, we analyzed the association among single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) gene, with clinical patterns of AIDS progression in antiretroviral treatment (ART)-naive HIV-infected patients. Methods: We conducted a retrospective study in 667 HIV-infected patients, who were classified within three groups according to their AIDS progression pattern (183 long-term non-progressors (LTNPs), 334 moderate progressors (MPs), and 150 rapid progressors (RPs)). Five VDR SNPs (rs11568820, rs4516035, rs2228570, rs1544410, and rs7975232) were genotyped using Agena Bioscience's MassARRAY platform. Results: Significant association results were found for rs2228570. Within all HIV patients, the presence of T allele at VDR rs2228570 SNP was protective against AIDS progression (ordinal outcome) under additive (adjusted odds ratio (aOR) = 0.75; p = 0.009), dominant (aOR = 0.69; p = 0.015), and codominant (aOR = 0.56; p = 0.017) inheritance models. In addition, the same allele was protective under additive and codominant inheritance models when we compared with LTNPs vs. RPs [aOR = 0.64 (p = 0.019) and aOR = 0.37 (p = 0.018), respectively] and when we compared MPs vs. RPs [aOR = 0.72 (p = 0.035) and aOR = 0.45 (p = 0.028), respectively]. Conclusions: The VDR rs2228570 T allele was related to a lower AIDS progression pattern in ART-naive HIV-infected patients. These findings expand upon the knowledge about HIV pathogenesis in untreated HIV-infected patients with different clinical outcomes.
Filiaciones:
Jiménez-Sousa MA:
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Madrid, Spain.
Jiménez JL:
Plataforma de Laboratorio, Hospital General Universitario "Gregorio Marañón", 28007 Madrid, Spain.
Fundación para la Investigación Biomédica, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain.
:
Unidad de Enfermedades Infecciosas, Hospital General de Elche & Universidad Miguel Hernández, 03202 Alicante, Spain.
Díez C:
Servicio Microbiología, Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio Marañon, 28007 Madrid, Spain.
Bernal-Morell E:
Servicio de Enfermedades Infecciosas, Hospital General Universitario Reina Sofia, 30003 Madrid, Spain.
Viciana P:
Servicio de Enfermedades Infecciosas, Hospital Virgen del Rocío, 41013 Seville, Spain.
Muñoz-Fernández MA:
Sección Inmunología, Laboratorio Inmuno Biología Molecular, Hospital General Universitario Gregorio Marañón, IiSGM, and Spanish HIV HGM BioBank, 28007 Madrid, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28007 Madrid, Spain.
Hosp 12 Octubre, Madrid, Spain.
Hosp Arnau Vilanova, Lleida, Spain.
Hosp Asturias, Asturias, Spain.
Hosp Bellvitge Princeps Espanya, Barcelona, Spain.
Hosp Castellon, Castellon De La Plana, Spain.
Hosp Clin Barcelona, Barcelona, Spain.
Hosp Donostia, San Sebastian, Spain.
Hosp Elche, Alicante, Spain.
Hosp Badalona Germans Trias & Pujol, Badalona, Spain.
Hosp Gregorio Maranon, Madrid, Spain.
Hosp Joan 23, Tarragona, Spain.
Hosp La Fe, Valencia, Spain.
Hosp La Paz Carlos III, Madrid, Spain.
Hosp La Princesa, Madrid, Spain.
Hosp Navarra, Pamplona, Spain.
Hosp Parc Tauli, Sabadell, Spain.
Hosp Ramon & Cajal, Madrid, Spain.
Hosp San Cecilio, Granada, Spain.
Hosp San Pedro, Logrono, Spain.
Hosp Son Dureta, Mallorca, Spain.
Green Published, gold, Green Submitted
|